Medicare Enrolled
Dr. Ahmed Abdel-Megid, M.D.
Internal Medicine · Somerville, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Abdel-Megid from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Abdel-Megid?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Abdel-Megid
Dr. Ahmed Abdel-Megid is an internal medicine specialist in Somerville, NJ, with 18 years of NPI registration. Based on federal Medicare data, Dr. Abdel-Megid performed 242,915 Medicare services across 2,888 unique beneficiaries.
Between the years covered by Open Payments, Dr. Abdel-Megid received a total of $28,313 from 51 pharmaceutical and/or device companies across 1091 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Abdel-Megid is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 0% volume in NJ
$28,313 industry payments
Medicare Practice Summary
Medicare Utilization ↗242,915
Medicare services
Top 0% in NJ for internal medicine
2,888
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~13,495 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) An injection of certolizumab pegol administered under the direct supervision of a physician. |
141,600 | $4 | $14 |
| Golimumab infusion (Simponi Aria) Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery. |
32,930 | $10 | $40 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
18,425 | $34 | $95 |
| Romosozumab injection (Evenity) for osteoporosis | 17,640 | $8 | $25 |
| Denosumab injection (Prolia/Xgeva) | 17,220 | $18 | $38 |
| Joint lubricant injection (TriVisc) An injection of hyaluronan or a derivative into a joint space. The dose specified is 1 milligram. |
3,276 | $7 | $30 |
| Hymovis intra-articular injection An injection of Hymovis, a hyaluronan derivative, administered directly into a joint space. |
2,905 | $13 | $50 |
| Joint lubricant injection (GenVisc) An injection of hyaluronan or its derivative into a joint space to provide lubrication and cushioning. |
2,000 | $6 | $20 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,879 | $105 | $208 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
1,334 | $65 | $169 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
671 | $116 | $399 |
| Methotrexate sodium, 5 mg | 640 | $0 | $2 |
| Ultrasound-guided large joint aspiration or injection This procedure uses ultrasound imaging to guide the removal of fluid from or the injection of medication into a large joint. |
509 | $90 | $265 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
219 | $8 | $24 |
| New patient office visit, complex (60-74 min) | 207 | $182 | $359 |
| Steroid injection (triamcinolone) A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered. |
203 | $1 | $10 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
193 | $59 | $176 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
185 | $6 | $115 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
170 | $155 | $226 |
| Injection, ibandronate sodium, 1 mg | 144 | $21 | $106 |
| Injection, methylprednisolone acetate, 40 mg | 128 | $6 | $17 |
| Bone density scan (DEXA) A test that uses low-dose X-rays to measure bone mineral density in the hip, pelvis, and spine. It helps assess bone strength and risk of fractures. |
103 | $45 | $167 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
86 | $26 | $126 |
| Methylprednisolone acetate injection, 20 mg A 20 mg injection of methylprednisolone acetate, a corticosteroid medication. This code specifies the drug and dosage administered. |
81 | $5 | $11 |
| Ultrasound-guided small joint aspiration or injection This procedure involves removing fluid from or injecting medication into a small joint while using ultrasound imaging to guide the needle placement. |
70 | $69 | $200 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
26 | $146 | $294 |
| Methylprednisolone acetate injection, 80 mg An injection of 80 mg of methylprednisolone acetate, a corticosteroid medication. |
26 | $9 | $25 |
| Ultrasound-guided joint aspiration or injection Removal of fluid from or injection into a medium-sized joint using ultrasound guidance to ensure accurate placement. |
25 | $84 | $175 |
| Ultrasound guidance for needle placement Use of ultrasound imaging to guide the precise placement of a needle during a medical procedure. |
20 | $51 | $300 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
21.4% high complexity
77.2% medium
1.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$28,313
Total received (2018-2024)
Avg $4,045/year across 7 years
Top 2% in NJ for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
51
Companies
1,091
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,771 (55.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$6,818 (24.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$5,724 (20.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,406
2023
$2,186
2022
$11,825
2021
$1,467
2020
$4,239
2019
$2,620
2018
$2,572
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$1,148
ABBVIE INC.
$558
GlaxoSmithKline, LLC.
$290
Amgen Inc.
$219
PFIZER INC.
$212
Janssen Scientific Affairs, LLC
$188
AstraZeneca Pharmaceuticals LP
$157
US Oncology Corporate, Inc.
$126
ANI Pharmaceuticals, Inc.
$120
Radius Health, Inc.
$72
DePuy Synthes Sales Inc.
$48
SCILEX PHARMACEUTICALS INC.
$44
Bioventus LLC
$44
Novartis Pharmaceuticals Corporation
$38
UCB, Inc.
$31
Organon Llc
$30
Fidia Pharma USA Inc.
$19
GENZYME CORPORATION
$19
Lilly USA, LLC
$17
Sandoz Inc.
$14
SOBI, INC
$13
Top 3 companies account for 58.6% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Biotech, Inc.
$6,473
Horizon Therapeutics plc
$5,701
ABBVIE INC.
$4,781
Amgen Inc.
$1,888
GlaxoSmithKline, LLC.
$1,545
PFIZER INC.
$1,454
Novartis Pharmaceuticals Corporation
$687
UCB, Inc.
$666
Janssen Scientific Affairs, LLC
$511
Lilly USA, LLC
$470
Genentech USA, Inc.
$462
GENZYME CORPORATION
$424
AbbVie, Inc.
$264
AbbVie Inc.
$242
Organon LLC
$206
Radius Health, Inc.
$169
Ferring Pharmaceuticals Inc.
$164
Mallinckrodt Hospital Products Inc.
$159
AstraZeneca Pharmaceuticals LP
$157
Bioventus LLC
$145
US Oncology Corporate, Inc.
$126
Flexion Therapeutics, Inc.
$124
ANI Pharmaceuticals, Inc.
$120
Boehringer Ingelheim Pharmaceuticals, Inc.
$109
Celgene Corporation
$106
DePuy Synthes Sales Inc.
$104
Merck Sharp & Dohme Corporation
$99
SANOFI-AVENTIS U.S. LLC
$96
Aurinia Pharma U.S., Inc.
$90
Boston Scientific Corporation
$85
E.R. Squibb & Sons, L.L.C.
$81
FIDIA PHARMA USA INC.
$76
MEDEXUS PHARMA, INC.
$64
Alexion Pharmaceuticals, Inc.
$51
Takeda Pharmaceuticals U.S.A., Inc.
$45
SCILEX PHARMACEUTICALS INC.
$44
Sobi, Inc
$39
Organon Llc
$30
Intercept Pharmaceuticals, Inc.
$30
Sandoz Inc.
$30
SOBI, INC
$29
Horizon Pharma plc
$28
Hikma Pharmaceuticals USA
$27
Fidia Pharma USA Inc.
$19
Pacira Therapeutics, Inc.
$16
SI-BONE, INC.
$15
Iroko Pharmaceuticals, LLC
$14
Sebela Pharmaceuticals Inc.
$13
Shire North American Group Inc
$13
MEDAC PHARMA, INC.
$12
West-Ward Pharmaceuticals
$11
Top 3 companies account for 59.9% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AVSOLA · Actemra · BENLYSTA · Bimzelx · COSENTYX · CUVITRU · Cimzia · DUROLANE · Durolane · EUFLEXXA · EVENITY · Enbrel · FORTEO · GELSYN 3 · GELSYN-3 · GENERAL PAIN MANAGEMENT · HADLIMA · HUMIRA · HYMOVIS · HYRIMOZ · Humira · Hymovis · IFUSE IMPLANT · ILARIS · INFLECTRA · KEVZARA · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · LYRICA · MONOVISC · Mitigare · NUCALA · OCALIVA · OFEV · ORENCIA · ORTHOVISC · Otezla · PENNSAID · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · REMICADE · RENFLEXIS · RHEUMATOID ARTHRITIS DISEASE · RIDAURA · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · SYNVISC-ONE · Strensiq · TALTZ · TAVNEOS · TREMFYA · Tavneos · Tymlos · ULTOMIRIS · Uloric · VIMOVO · VIVLODEX · WATCHMAN · WATCHMAN Access System · XELJANZ · ZTLido · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (56%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 2% for internal medicine in NJ.
Geographic Context
Internal medicine physicians within 10 mi
1,796
Per 100K population
518.8
County median income
$135,960
Nearest hospital
ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL - SOMERSET
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Abdel-Megid is a mixed practice specialist, with above-average Medicare volume (top 0% in NJ), with low-engagement industry engagement in the top 2% of NJ peers, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Abdel-Megid experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Abdel-Megid performed 141,600 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Abdel-Megid receive payments from pharmaceutical companies?
Yes. Dr. Abdel-Megid received a total of $28,313 from 51 companies across 1,091 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Abdel-Megid's costs compare to other internal medicine physicians in Somerville?
Dr. Abdel-Megid's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Abdel-Megid) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Somerville
Browse internal medicine physicians in Somerville ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in NJ
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in NJ
Which NJ internal medicine physicians receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Horizon Therapeutics plc Payments to Doctors
See all physicians who received payments from Horizon Therapeutics plc.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology